Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
The controversy over vasopressor use in shock leaves open optimal strategies; prospective trials needed to guide practice.
THE rationale for the use of vasopressor agents in the treatment of shock is controversial. The principal objection to their use is that during shock, sympathetic and adrenergic activity is increased while the arterial vascular bed is already constricted. Hemodynamic measurements indicate that the arterial vascular resistance is usually high. Arteries and arterioles are constricted, particularly in splanchnic vascular beds.1 Since sympathomimetic drugs produce additional narrowing of the vessels it is postulated that their use results in further reduction of effective blood flow to vital organs, additional tissue ischemia and potentiation of shock. The search for nonadrenergic vasopressor agents led . . .
No takes yet. Share an insight, caveat, or question.
Udhoji et al. (1964) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: